FCMI
Foresite Capital Management II Portfolio holdings
AUM
$29.2M
This Quarter Return
-4.7%
1 Year Return
+44.84%
3 Year Return
-66.21%
5 Year Return
-37.37%
10 Year Return
–
AUM
$287M
AUM Growth
+$287M
(+0.18%)
Cap. Flow
+$24.4M
Cap. Flow
% of AUM
8.51%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
13
New
3
Increased
3
Reduced
–
Closed
3
Top Buys
| 1 |
Insmed
INSM
|
$10.1M |
| 2 |
ALDR
Alder Biopharmaceuticals, Inc.
ALDR
|
$8.16M |
| 3 |
AIMT
Aimmune Therapeutics, Inc.
AIMT
|
$7M |
| 4 |
ADAP
Adaptimmune Therapeutics
ADAP
|
$4.49M |
| 5 |
Sangamo Therapeutics
SGMO
|
$877K |
Top Sells
| 1 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
$3.89M |
| 2 |
uniQure
QURE
|
$2.14M |
| 3 |
LOXO
Loxo Oncology, Inc
LOXO
|
$1M |
Sector Composition
| 1 | Healthcare | 31.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AIMT
1
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $106M | 35.15% |
3,319,945
+219,799
| +7% | +$7M |
|
|
AERI
2
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $90.7M | 30.19% |
1,672,714
| – | – |
|
|
EPZM
3
DELISTED
Epizyme, Inc
EPZM
| $27.7M | 9.2% |
1,558,108
| – | – |
|
|
4
Insmed
INSM
$28.8B
| $21.8M | 7.25% |
967,636
+448,991
| +87% | +$10.1M |
|
|
ALDR
5
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $21.4M | 7.12% |
1,686,220
+642,388
| +62% | +$8.16M |
|
|
XLRN
6
DELISTED
Acceleron Pharma Inc.
XLRN
| $9.57M | 3.18% |
244,756
| – | – |
|
|
ADAP
7
Adaptimmune Therapeutics
ADAP
$15.6M
| $4.49M | 1.49% |
+400,000
| New | +$4.49M |
|
8
Denali Therapeutics
DNLI
$2.23B
| $3.7M | 1.23% |
250,000
| – | – |
|
|
9
Sangamo Therapeutics
SGMO
$157M
| $877K | 0.29% |
+46,138
| New | +$877K |
|
10
Ardelyx
ARDX
$1.53B
| $808K | 0.27% |
+159,967
| New | +$808K |
|
|
11
uniQure
QURE
$896M
| – | – |
-109,350
| Closed | -$2.14M |
|
|
LOXO
12
DELISTED
Loxo Oncology, Inc
LOXO
| – | – |
-11,900
| Closed | -$1M |
|
|
JUNO
13
DELISTED
Juno Therapeutics, Inc.
JUNO
| – | – |
-85,000
| Closed | -$3.89M |
|